HU
HURA.US TuHURA Biosciences Inc
- Market cap
- USD 88.6M
- P/E
- -
- P/B
- 4.84x
- ROE
- -135.3%
- Dividend yield
- 0.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is HURA.US undervalued?
Graham numberThe Graham number of TuHURA Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TuHURA Biosciences Inc fundamental analysis
No fundamental analysis for TuHURA Biosciences Inc yet.
TuHURA Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta recep…
Full company profileTuHURA Biosciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
TuHURA Biosciences Inc annual financial statements
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | -16.7K | -24.5K | -16.3K | -10.0K | -32.0K | -60.0K | -60.0K | -55.0K | -117K | - | - |
| Operating Income | -8.32M | -11.2M | -8.40M | -8.14M | -21.6M | -22.7M | -14.8M | -8.45M | -17.6M | -31.8M | -22.6M |
| EBITDA | -8.07M | -11.1M | -8.03M | -9.12M | -38.1M | -21.7M | -14.3M | -8.14M | -17.4M | -29.4M | -22.5M |
| Net Income | -8.08M | -11.1M | -8.05M | -9.13M | -38.3M | -22.7M | -14.6M | -8.32M | -21.7M | -30.1M | -25.6M |
| EPS | -11,747 | -9,344 | -5,471 | -1,529 | -2,589 | -814 | -316 | -11 | -1.16 | -0.63 | -0.39 |
| Balance Sheet | |||||||||||
| Total Assets | 7.91M | 7.07M | 4.04M | 2.94M | 13.5M | 6.40M | 15.2M | 4.36M | 20.0M | 27.4M | 36.2M |
| Total Liabilities | 1.33M | 1.64M | 2.07M | 2.68M | 2.96M | 7.15M | 2.89M | 5.92M | 5.37M | 6.42M | 17.3M |
| Shareholders' Equity | 6.58M | 5.44M | 1.97M | 263K | 10.6M | -748K | 12.3M | -1.56M | 14.6M | 20.9M | 19.0M |
| Cash & Short-term Investments | 6.59M | 5.97M | 3.72M | 2.39M | 10.5M | 5.55M | 14.3M | 3.67M | 12.7M | 3.62M | 1.89M |
| Total Debt | - | - | - | - | - | 644K | 138K | 2.34M | 203K | 700K | 9.56M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.02M | -9.85M | -6.33M | -7.93M | -18.9M | -6.56M | -7.51M | -12.0M | -14.7M | -27.6M | -20.0M |
| Capital Expenditure | 1.00 | 9.85M | 5.00 | 0.00 | 8.00K | 3.28K | 36.3K | 79.2K | 57.9K | 76.1K | 0.00 |
| Free Cash Flow | -8.02M | - | -6.33M | -7.93M | -18.9M | -6.57M | -7.54M | -12.0M | -14.8M | -27.7M | -20.0M |
| Ratios | |||||||||||
| ROE | -122.9% | -204.9% | -409.1% | -3,470.0% | -362.0% | - | -119.1% | - | -148.6% | -143.6% | -135.3% |
| ROA | -102.2% | -157.4% | -199.3% | -310.6% | -282.8% | -354.0% | -96.4% | -190.7% | -108.6% | -109.9% | -70.7% |
| Debt to Equity | - | - | - | - | - | - | 0.01x | - | 0.01x | 0.03x | 0.50x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
TuHURA Biosciences Inc dividends
- Dividend yield
- 0.01%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | USD 8.36K | 0.00 | - |
| 2025 | - | - | - |
| 2024 | USD 6.00K | 0.01 | - |
| 2023 | USD 8.00K | 0.17 | - |
| 2022 | USD 8.00K | 0.29 | - |
| 2021 | USD 8.00K | 0.54 | - |
| 2020 | USD 8.00K | 1.34 | - |
| 2019 | USD 8.36K | 5.68 | - |
| 2018 | USD 8.36K | 7.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:35 on Oct 18, 2024.
Who owns TuHURA Biosciences Inc
- Insiders 34.68%
- Institutions 14.20%
- Public & others 51.12%
- Shares outstanding 63.7M
- Free float 39.7M
Top funds holding HURA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.74M | 2.73% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 212K | 0.33% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 130K | 0.20% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 76.3K | 0.12% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 64.8K | 0.10% | 0.00% | Sep 2026 |
| Vanguard Balanced Index Inv | 29.9K | 0.05% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 22.1K | 0.03% | -47.62% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 9.68K | 0.02% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 9.13K | 0.01% | -17.27% | Sep 2026 |
| Victory Extended Market Index | 4.76K | 0.01% | -15.14% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 242.00 | 0.00% | +51.25% | Jun 2026 |
| BlackRock Diversified Equity Alpha Inst | 89.00 | 0.00% | 0.00% | Jul 2026 |
Top institutions holding HURA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 2.27M | 3.56% | +9.34% | Jun 2026 |
| Northern Trust Corp | 1.62M | 2.54% | +443.63% | Jun 2026 |
| BlackRock Inc | 690K | 1.08% | -71.84% | Jun 2026 |
| Geode Capital Management, LLC | 484K | 0.76% | -50.94% | Jun 2026 |
| Millennium Management LLC | 455K | 0.71% | 0.00% | Jun 2026 |
| AQR Capital Management LLC | 425K | 0.67% | -30.07% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 251K | 0.39% | -12.52% | Jun 2026 |
| Citadel Advisors Llc | 232K | 0.36% | 0.00% | Jun 2026 |
| State Street Corp | 188K | 0.30% | -63.27% | Jun 2026 |
| Jane Street Group LLC | 164K | 0.26% | 0.00% | Jun 2026 |
| Apollon Wealth Management, LLC | 157K | 0.25% | -0.94% | Jun 2026 |
| Qube Research & Technologies | 146K | 0.23% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 143K | 0.22% | +501.09% | Jun 2026 |
| The Goldman Sachs Group Inc | 132K | 0.21% | +87.58% | Jun 2026 |
| Bank of New York Mellon Corp | 122K | 0.19% | -42.50% | Jun 2026 |
| XTX Topco Ltd | 100K | 0.16% | +772.27% | Jun 2026 |
| Emerald Investment Partners, LLC | 91.5K | 0.14% | 0.00% | Jun 2026 |
| Aster Capital Management (DIFC) Ltd | 89.7K | 0.14% | 0.00% | Jun 2026 |
| CapTrust Financial Advisors | 88.4K | 0.14% | 0.00% | Jun 2026 |
| Cetera Investment Advisers | 61.6K | 0.10% | -56.06% | Jun 2026 |
TuHURA Biosciences Inc company profile
- Company name
- TuHURA Biosciences Inc
- Ticker
- HURA.US
- Exchange
- USA Stocks
- Listed since
- Feb 22, 2013
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Fiscal year end
- June
- Address
- 10500 University Center Drive, Tampa, FL, United States, 33612
- Phone
- 813 875 6600
- Website
- tuhurabio.com
About TuHURA Biosciences Inc
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also developing Immune Fx; IFx-3.0, an mRNA innate immune agonist candidate for intravenous or autologous whole cell administration for blood-related cancers. The company was formerly known as Morphogenesis, Inc. and changed its name to TuHURA Biosciences, Inc. in December 2023. The company was founded in 1995 and is based in Tampa, Florida. TuHURA Biosciences, Inc. operates as a subsidiary of CohBar, Inc.
TuHURA Biosciences Inc management
6- Dr. James A. Bianco M.D.President, CEO & Director · born 1957
- Mr. Dan Dearborn CPAExecutive VP of Finance & CFO · born 1967
- Mr. Michael LawmanCo-Founder
- Ms. Patricia LawmanCo-Founder
- Mr. Michael KrsulichHead of Quality Assurance
- Ms. Amanda GarofaloSenior Vice President of Clinical Operations